ARLO - ROFL - don't let these losers get to ya.... You're taking this too seriously.
Will check out that other board tonite. Mellow out.
Hey Arlo, didn't like what I was reading on that board - enough more ons on this board.
How's things with you?? I see COCP making a big move today, still have 55K of that puppy, too.
SAMADI: PROSTATE CANCER IS NOT JUST AN OLDER MAN’S DISEASE
New genetic tests including the 4K Score, PCA3, Oncotype DX and Prolaris have launched in the past year and are working to give us more information about the patient’s risk for the disease. If the patient is diagnosed, these new tools can help direct a better treatment path. These are game changers in terms of the entire process of diagnosing and treating prostate cancer.
Pretty convincing stuff:
• In this large-scale, multicenter, randomized, double-blind, placebo-controlled trial, the authors evaluated 1369 patients receiving moderately emetogenic chemotherapy to determine if the addition of rolapitant to a serotonin receptor antagonist and dexamethasone would result in improved control of delayed chemotherapy-induced emesis. Patients in the rolapitant, granisetron, and dexamethasone (R + GD) groups had significantly more complete responses (no emesis or use of rescue medication) than those in the placebo, granisetron, and dexamethasone (P + GD) group (71% vs 62%, respectively). Both regimens were tolerated well, with no significant difference in adverse events between the two groups.
• During the 5-day at-risk period following treatment with moderately emetogenic chemotherapy or regimens containing an anthracycline and cyclophosphamide, combined treatment with rolapitant, a 5-HT3 receptor antagonist, and dexamethasone was well-tolerated and effectively prevented chemotherapy-induced nausea and vomiting in cancer patients.
Opko Health Inc. and TESARO Inc Investors Have an Exciting Week Ahead
An FDA decision date for these two companies is approaching fast -- investors be on your toes!
The Motley Fool
September 1, 2015
Investors in small cap-biopharmaceutical companies Opko Health (NYSE:OPK) and TESARO (NASDAQ:TSRO) should start off the month of September with a bang. These two companies are poised to hear back from the FDA about their drug Rolapitant very soon. The drug was initially submitted for regulatory approval in September of last year, and companies were given a review date of this Friday, September 5. If approved, Opko expects to launch the product in the fourth quarter of this year.
Revolutionizing cancer patient care
Rolapitant is an investigational drug that is designed to help reduce nausea and vomiting in patients who are undergoing chemotherapy. The technical name of this side effect is Chemotherapy-Induced Nausea and Vomiting, or CINV. In clinical studies, Rolapitant was shown to be effective in helping patients control their nausea and vomiting symptoms for 5 days, which compares quite favorably to the 1 to 2 days of relief that other currently-available treatments provide.
Rolapitant works by binding to a Neurokinin-1 receptors in the brain, which have been shown to play a role in triggering the feeling of nausea. Rolapitant disrupts these receptors interactions with neurokinin called Substance P, which in clinical results were shown to help patients control their nausea symptoms.
While it may seem like this is a "nice to have" drug rather than a life-saver, CINV is actually quite a serious medical problems that occurs in up to 90% of patients who are receiving chemotherapy. CINV can also lead to very serious problems like dehydration and malnutrition, and can even cause patients to discontinue chemotherapy altogether.
A hot-potato history
During the course of its development, Rolapitant has been passed around between a few different companies
Extensive phlebotomy draw stations offer synergistic opportunity for efficient
commercialization of 4Kscore test for high-grade prostate cancer
~175 BRLI patient service centers located throughout the US for collection of patient
the national marketing,
sales, and distribution resources of
BRLI to enhance sales of OPKO’s diagnostic platforms
~420 sales and marketing personnel
~5,000 people working together to support the needs of clients and patients
Near-term profitability supports the development of existing pharmaceutical pipeline
Well put, Burnaka. Difference of opinion, we get to buy cheap stock.
Really like the way ARRY is trading, if the IBB would stabilize, ARRY would be at $7 pretty quickly.